In vivo metabolism of proapolipoprotein A-I in Tangier disease. (original) (raw)

Research Article Free access | 10.1172/JCI113266

R E Gregg, L A Zech, M S Meng, C Bishop, R Ronan, and H B Brewer Jr

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Bojanovski, D. in:JCI |PubMed |Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Gregg, R. in:[JCI](/search/results?q=author.first%5Fname%3A%22R E%22+author.last%5Fname%3A%22Gregg%22&search%5Ftype=advanced) |PubMed |Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Zech, L. in:[JCI](/search/results?q=author.first%5Fname%3A%22L A%22+author.last%5Fname%3A%22Zech%22&search%5Ftype=advanced) |PubMed |Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Meng, M. in:[JCI](/search/results?q=author.first%5Fname%3A%22M S%22+author.last%5Fname%3A%22Meng%22&search%5Ftype=advanced) |PubMed |Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Bishop, C. in:JCI |PubMed |Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Ronan, R. in:JCI |PubMed |Google Scholar

Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Find articles by Brewer, H. in:[JCI](/search/results?q=author.first%5Fname%3A%22H B%22+author.last%5Fname%3A%22Brewer%22&search%5Ftype=advanced) |PubMed |Google Scholar

Published December 1, 1987 -More info

Published December 1, 1987 -Version history

View PDF

Abstract

Tangier disease is a rare familial disorder characterized by extremely low levels of apolipoprotein A-I (apoA-I) and high density lipoproteins (HDL). In normal subjects, proapoA-I is secreted into plasma and converted to mature apoA-I by the cleavage of the amino-terminal six amino acids with the major isoprotein in plasma being mature apoA-I. In contrast, in Tangier disease there is a marked relative increase of proapoA-I as compared with mature apoA-I. ProapoA-I and mature apoA-I were isolated from normal and Tangier disease subjects, radio-labeled, and autologous apoA-I isoproteins injected into normal and Tangier subjects. The in vivo catabolism and conversion of proapoA-I and mature apoA-I in normal and Tangier disease subjects were quantitated. A comparison of the rate of catabolism of apoA-I isoproteins from plasma revealed a significantly faster rate of catabolism of both isoproteins of apoA-I in Tangier subjects when compared with normal subjects. The fractional conversion rate of proapoA-I to mature apoA-I was 3.9 d-1 in normal subjects and 3.6 d-1 in Tangier subjects. The results indicate that (a) apoA-I enters plasma as the pro isoprotein in both normal and Tangier subjects, (b) Tangier disease subjects have a normal fractional rate of conversion of proapoA-I to mature apoA-I, (c) proapoA-I is catabolized at the same rate as mature apoA-I in Tangier subjects, and (d) Tangier subjects catabolize both pro and mature apoA-I at a much greater rate than do normal subjects. Therefore, the relative increase in proapoA-I in Tangier disease is due to a marked decrease in mature apoA-I resulting from rapid catabolism of both pro- and mature apoA-I and not to defective conversion of proapoA-I to mature apoA-I.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history